Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3Thoracic 1Genitourinary 1CNS 1

Conditions

Neoplasms 2Melanoma 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Recurrence 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Central Nervous System Neoplasms 1Brain Neoplasms 1Brain Diseases 1

Interventions

avapritinib 2Imatinib Mesylate 2trametinib 1sargramostim 1ripretinib 1guadecitabine 1dabrafenib 1Trabectedin 1Thalidomide 1Specimen Handling 1Oxaliplatin 1Nivolumab 1Midazolam 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Ipilimumab 1Floxuridine 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Cetuximab 1Capecitabine 1CTLA-4 Antigen 17-hydroxystaurosporine 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × Midazolam × CNS × Clear all
NCT04908176 2024-12-13

A Drug-drug Interaction Study of Avapritinib and Midazolam

Blueprint Medicines Corporation

Phase 1 Completed
10 enrolled
CNSGastrointestinalSarcoma

Glioblastoma, Neoplasms, Recurrence, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡